FDAAA 801 & ClinicalTrials.gov

Civil monetary penalties of up to $15,107 per day of violation, assessed under 21 U.S.C. 333(f)(3)(B) once the correction windows close. The sequence matters more than the headline number: FDA first issues a Preliminary Notice of Noncompliance and allows 30 days to correct; if that lapses, a formal Notice of Noncompliance follows with another 30 calendar days; only after that can penalties be assessed, alongside possible injunction or criminal prosecution. The reputational exposure lands first, because FDA publishes those notices in its public enforcement table where partners, investors and journalists can find them long before any money is at stake.

Enrollment of the first participant in an applicable clinical trial starts the clock, and initial ClinicalTrials.gov registration is due within 21 calendar days (42 CFR 11.24(a)). The trigger is the day the first participant enrolls — not the day the registry team hears about it — so the date has to arrive from CTMS enrollment events rather than a monthly status call. Missing the window is one of the most common early compliance failures, and it is not quietly recoverable: the registration date sits on the public record, and TrialAssure REGISTRY® is built to watch the trigger instead of the calendar.

Summary results are generally due within 12 months of the primary completion date under 42 CFR 11.44(a). Two mechanisms can move that date, and neither is automatic: a certification of delayed submission for an unapproved product or unapproved new use, and a good-cause extension request under 42 CFR 11.44(e), which NIH grants or denies. Both must be filed before the standard deadline expires. Budget for the build as well — ClinicalTrials.gov results are mostly structured data tables, plus the protocol and statistical analysis plan, and NLM’s quality-control review can send a submitted record back for correction, which consumes calendar time you no longer have.

Late awareness of trigger events, plus manual tracking. First-participant-in and primary completion are recorded in clinical operations systems; when the registry team hears about them on a monthly status call, part of the 21-day or 12-month window is already spent. Only ~41% of applicable U.S. trials met their ClinicalTrials.gov results reporting deadline in the Lancet’s analysis. The other two failure points are the applicability determination — deciding and documenting which studies are applicable clinical trials under 42 CFR 11.22 — and evidence, because a Pre-Notice gives you 30 days to demonstrate correction. Automating the clocks and keeping a submission log is the fix.

No — Phase 1 drug trials and small feasibility device studies are excluded from the applicable clinical trial definition in 42 CFR Part 11. Two caveats: separate NIH policy requires registration and results reporting for any NIH-funded clinical trial, including Phase 1, and the EU CTR covers Phase 1 trials conducted in the EU/EEA. Exempt in the US does not mean exempt everywhere — the determination has to be made per study, per jurisdiction.

Only when the trial has a US nexus. An overseas study becomes an applicable clinical trial if it has at least one site in the US or a US territory, is conducted under an FDA IND or IDE, or studies a product manufactured in the US and exported for research. A trial with none of those links falls outside FDAAA 801 — though other regimes, such as the EU CTR, may still require disclosure.

Yes. If the trial studies an unapproved, unlicensed, or uncleared product — or an unapproved new use — the responsible party can file a certification of delayed submission under 42 CFR 11.44(b)-(c). Results are then due 30 days after FDA approval, licensure, or clearance, or 2 years after the certification date, whichever comes first. Only one certification is allowed per trial, and a separate good-cause extension exists. REGISTRY tracks certification clocks alongside the standard 12-month deadline.

The sponsor, by default. Under 42 CFR Part 11 the sponsor is the responsible party unless it formally designates a qualified principal investigator, and for trials run under an IND or IDE the IND/IDE holder is considered the sponsor. The designation matters because Pre-Notices, Notices of Noncompliance, and civil money penalties attach to the responsible party of record — not to CROs or collaborators.

Not yet — FDA’s public enforcement table lists no civil money penalties assessed. But the machinery is running: 246 Preliminary Notices of Noncompliance posted through June 2026, 8 formal Notices of Noncompliance since 2021, and on March 30, 2026 FDA contacted more than 2,200 sponsors and researchers about missing results across 3,000+ trials. Every uncorrected day carries $15,107 in exposure; the platform keeps that exposure visible portfolio-wide.

No. Meeting ClinicalTrials.gov requirements satisfies US law only. Trials conducted in the EU/EEA must be separately entered in CTIS under Regulation (EU) No 536/2014, with a summary of results due 12 months after the end of the trial (6 months for pediatric studies) plus a layperson summary. The two systems have different data structures, different clocks, and different triggers, so multinational sponsors run parallel disclosure calendars for the same study.